Adma Biologics reported $575.86M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Adma Biologics USD 575.86M 47.66M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 707.96M 63.14M Sep/2026
Omeros USD 69.65M 26.53M Jun/2025
Takeda JPY 3T 153.11B Sep/2026